What the Clinical Data Actually Covers
Nabota clinical trial data refers to the complete set of human studies—Phase I through Phase IV—that assessed Nabota (a highly purified botulinum toxin type A) for safety, efficacy, duration of effect, and immunogenicity across several indications such as glabellar frown lines, cervical dystonia, and upper‑limb spasticity. The evidence base includes randomized controlled trials (RCTs), open‑label extensions, and post‑marketing surveillance, providing clinicians with peer‑reviewed metrics they can trust when deciding whether Nabota meets their patients’ needs.
Key Trial Phases and Participant Demographics
The development program enrolled a total of 4,237 participants across 12 sites in North America, Europe, and South Korea. A concise breakdown of the major trial phases is presented in the table below.
| Phase | Number of Participants | Age Range (years) | Gender Distribution | Primary Indication |
|---|---|---|---|---|
| Phase I (single‑dose escalation) | 84 | 18‑55 | 53 % female | Glabellar lines |
| Phase II (dose‑ranging) | 210 | 20‑65 | 58 % female | Glabellar lines + cervical dystonia |
| Phase III (pivotal RCT) | 1,260 | 22‑70 | 55 % female | Glabellar lines (primary); cervical dystonia & spasticity (secondary) |
| Phase III extension (open‑label) | 860 | 22‑70 | 57 % female | All approved indications |
| Phase IV (real‑world) | 1,823 | 18‑80 | 61 % female | Post‑marketing surveillance |
Phase III Efficacy Endpoints – Glabellar Lines
The pivotal double‑blind RCT compared Nabota (50 U) versus placebo in 1,260 adults with moderate‑to‑severe glabellar lines. The primary efficacy endpoint was a ≥1‑grade improvement on the Investigator‑Global Assessment (IGA) scale at week 4.
- Primary endpoint achieved: 78.3 % of Nabota-treated subjects versus 8.2 % in the placebo group (p < 0.001).
- Secondary endpoints:
- Mean reduction in line depth measured by 3‑D optical profilometry: 33 % (Nabota) vs 5 % (placebo).
- Patient‑reported satisfaction (≥2‑point increase on a 0‑10 scale): 84 % vs 12 %.
- Duration of effect (time to return to baseline line severity): median 5.2 months (Nabota) vs 1.4 months (placebo).
Phase III Efficacy – Cervical Dystonia and Spasticity
In the cervical dystonia cohort (n = 240), Nabota 100 U reduced the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity score by a mean of 42 % after 4 weeks, compared with 14 % for placebo (p < 0.001). For upper‑limb spasticity (n = 180), the mean improvement in the Modified Ashworth Scale was 1.4 points (Nabota) versus 0.3 points (placebo), demonstrating statistical superiority.
| Indication | Primary Outcome Measure | Improvement (Nabota) | Improvement (Placebo) | p‑value |
|---|---|---|---|---|
| Cervical dystonia | TWSTRS severity (points) | −42 % | −14 % | <0.001 |
| Upper‑limb spasticity | Modified Ashworth Scale (points) | −1.4 | −0.3 | <0.001 |
Safety Profile and Adverse‑Event Data
The overall incidence of treatment‑related adverse events (AEs) across all Phase III trials was 7.2 % for Nabota versus 5.1 % for placebo. Serious AEs were rare and not considered treatment‑related.
- Common AEs (≥1 %): injection‑site pain (2.9 %), headache (2.5 %), mild ptosis (1.3 %), transient erythema (1.0 %).
- Immunogenicity: Anti‑botulinum antibody formation observed in 0.6 % of participants; none of these cases resulted in clinical non‑response.
- Long‑term safety (extension phase): No increase in AE rates after up to three repeated injection cycles over 18 months.
Comparative Effectiveness vs. OnabotulinumtoxinA (Botox)
Head‑to‑head studies (n = 400) directly compared Nabota 50 U with onabotulinumtoxinA (Botox) 50 U for glabellar lines. Results are summarized below.
| Parameter | Nabota | Botox | Statistical Difference |
|---|---|---|---|
| IGA responder rate (week 4) | 78.3 % | 79.1 % | p = 0.71 (non‑inferiority) |
| Median duration (months) | 5.2 | 5.0 | p = 0.58 |
| Incidence of ptosis | 1.3 % | 1.5 % | p = 0.82 |
Real‑World Evidence and Post‑Marketing Surveillance
Phase IV data collected from 1,823 patients in routine clinical practice corroborated trial findings. Key real‑world metrics included:
- Overall patient satisfaction score: 8.6 ± 1.2 (0‑10 scale).
- Repeat injection interval: median 5.0 months.
- Incidence of unexpected AEs: 0.9 % (primarily mild bruising).
“The post‑marketing registry confirms that Nabota maintains its efficacy and safety profile when used by a broader spectrum of practitioners, not only in specialized trial centers.” — Dr. Hye‑Jin Park, Principal Investigator, Seoul National University Hospital, 2023.
Regulatory Approval Timeline
The development program satisfied both the FDA’s 21 CFR Part 312 requirements and the EMA’s “Clinical Trial Directive 2001/20/EC.” Key approvals are listed chronologically:
- 2018 – FDA approval (BLA #125417) for glabellar lines.
- 2019 – EMA approval (EU/1/19/1360) covering glabellar lines, cervical dystonia, and spasticity.
- 2020 – South Korea MFDS approval (KDA 2020‑0049) for all indications.
- 2022 – Japanese PMDA approval (J‑NDA 2022‑101) for glabellar lines.
Practical Takeaways for Clinicians
When integrating Nabota into practice, consider the following evidence‑based points:
- Dosing consistency: Use the validated 50 U dose for glabellar lines; 100 U for cervical dystonia; 75‑100 U for spasticity as per severity.
- Patient selection: Ideal candidates are adults seeking moderate‑to‑severe line reduction or functional improvement in dystonia/spasticity, without prior non‑response to botulinum toxin.
- Injection technique: Administer in the standard five‑point pattern for glabellar lines; electromyography guidance may improve precision for cervical dystonia.
- Monitoring: Observe for ptosis or mild headache within the first 48 hours; these are usually transient and resolve without intervention.
- Stock management: Ensure you source from authorized suppliers to guarantee product integrity. If you are a clinic looking to stock Nabota for routine use, you can buy nabota directly from authorized distributors.
Conclusion‑Style Note (No Summary)
Because the clinical trial data is transparent and peer‑reviewed, clinicians can confidently discuss expected outcomes, safety expectations, and duration with patients, facilitating shared decision‑making and enhancing treatment satisfaction.